Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Melanoma 8Head and Neck Neoplasms 8Lung Neoplasms 6Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Stomach Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Glioblastoma 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable or Metastatic Solid Tumors 1Thymus Neoplasms 1Thymoma 1Spinocerebellar Degenerations 1

Interventions

Paclitaxel 95Carboplatin 76pembrolizumab 72Cisplatin 28Bevacizumab 27Letrozole 22Radiotherapy 21Doxorubicin 21Megestrol Acetate 20lenvatinib 19olaparib 18Taxes 17Docetaxel 17Nivolumab 16Specimen Handling 15Metformin 15dostarlimab 14Magnetic Resonance Spectroscopy 14Gemcitabine 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11Biopsy 11temsirolimus 10abemaciclib 10atezolizumab 9Radiation 9Early Intervention, Educational 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Endometrial Neoplasms × epacadostat × Clear all
NCT04463771 2025-12-10

POD1UM-204

Incyte Corporation

Phase 2 Active not recruiting
206 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT03277352 2021-07-22

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Terminated
10 enrolled 14 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡